Stockscreener 앱 받기
4.23
7.91%
0.31
시간 외 거래:
4.26
0.03
+0.71%
전일 마감가:
$3.92
열려 있는:
$3.96
하루 거래량:
1.85M
Relative Volume:
4.39
시가총액:
$278.57M
수익:
-
순이익/손실:
$-26.25M
주가수익비율:
-10.32
EPS:
-0.4099
순현금흐름:
$-20.05M
1주 성능:
+49.73%
1개월 성능:
+69.20%
6개월 성능:
+4.96%
1년 성능:
+68.53%
1일 변동 폭
$3.8801
$4.37
1주일 범위
$2.71
$4.37
52주 변동 폭
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
명칭
Galectin Therapeutics Inc
전화
678-620-3186
주소
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.23 | 258.16M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
480.18 | 120.61B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
620.14 | 65.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.65 | 53.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.17 | 39.26B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
178.17 | 36.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 재개 | H.C. Wainwright | Buy |
| 2020-08-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-13 | 개시 | B. Riley FBR | Buy |
| 2017-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-19 | 개시 | ROTH Capital | Buy |
| 2017-03-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | 다운그레이드 | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-09-21 | 개시 | H.C. Wainwright | Buy |
| 2014-08-01 | 다운그레이드 | Aegis Capital | Buy → Hold |
| 2014-07-30 | 재확인 | MLV & Co | Buy |
| 2014-07-29 | 재확인 | MLV & Co | Buy |
| 2014-04-02 | 재확인 | MLV & Co | Buy |
| 2014-02-10 | 재확인 | Aegis Capital | Buy |
| 2014-01-09 | 재확인 | Aegis Capital | Buy |
| 2013-12-03 | 개시 | MLV & Co | Buy |
| 2013-08-19 | 재확인 | Aegis Capital | Buy |
모두보기
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com Canada
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com Canada
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH - Yahoo Finance
Form 144 GALECTIN THERAPEUTICS INC For: 23 June By Investing.com - Investing.com Australia
Form 144 GALECTIN THERAPEUTICS INC For: 23 June - Investing.com UK
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
GALT affiliate notifies sale of 8,125 shares (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program - GuruFocus
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Asianet Newsable
Galectin Therapeutics stock surges on FDA trial agreement - Investing.com
Galectin Therapeutics clears FDA Type C milestone, shares react on NASDAQ - Ad-hoc-news.de
GALT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $11 - GuruFocus
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 T - GuruFocus
Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans - marketscreener.com
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 Trial Preparation - GuruFocus
Galectin reaches FDA agreement on Phase 3 trial for belapectin - Investing.com
Galecti, FDA agree on Phase 3 trial for MASH drug (GALT:NASDAQ) - Seeking Alpha
Galectin Therapeutics Secures FDA Agreement for Phase 3 Belapectin Trial in MASH Cirrhosis and Portal Hypertension 1 – Minichart - Minichart
Galectin Advances Belapectin to Phase 3 After FDA Alignment - TipRanks
Galectin Therapeutics Reaches FDA Agreement on Phase 3 Endpoint and Regulatory Path for Belapectin Full Approval - Quiver Quantitative
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension - Yahoo Finance
Galectin Announces FDA Agreement on Phase 3 Endpoint and Q3 2026 Protocol Filing for Belapectin - TradingView
FDA backs Galectin (NASDAQ: GALT) belapectin Phase 3 plan in MASH - Stock Titan
GALT Stock Surges 22%On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Mena FN
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galectin Therapeutics Inc (GALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Galectin Therapeutics Inc (GALT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Galectin Therapeutics Inc (GALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galectin Therapeutics Inc (GALT) Valuation: PE, PB & Fair Value Analysis - TradingKey
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Investor ScrutinyQuarterly Profit Report - newsline.com
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineDividend Earnings Report - newsline.com
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock By Investing.com - Investing.com India
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 568 shares after option exercise - Stock Titan
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Galectin Therapeutics (GALT) Unveils New Insights from NAVIGATE Trial at EASL 2026 - GuruFocus
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical Development ContinuesPre-Earnings Setup - thelegaladvocate.com
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis - The Manila Times
Galectin Therapeutics (GALT) Holds Near $2.50 After Modest DeclineATR Stop - Newser
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GALT Q1 2026 Earnings: Narrowed Loss Amid Clinical Progress, Stock RallyGuidance Accuracy Score - The Legal Advocate
Galectin Therapeutics (GALT) Q1 2026 Results Miss Estimates — EPS $-0.08 vs $-0.06Special Dividend Alert - Newser
Number of shareholders of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Galectin Therapeutics Inc (GALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.76%
자본화:
|
볼륨(24시간):